Poniard Pharmaceuticals (PARD) Stock Price & Analysis
PARD Stock Chart & Stats
- Day’s Range
- $0.31 - $0.31
- 52-Week Range
- $0.31 - $0.31
- Previous Close
- $0.31
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $150
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- $14.47M
- Price to Earnings (P/E)
- 0.0
- Beta
- 141.33
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
PARD FAQ
What was Poniard Pharmaceuticals’s price range in the past 12 months?
What is Poniard Pharmaceuticals’s market cap?
When is Poniard Pharmaceuticals’s upcoming earnings report date?
Is Poniard Pharmaceuticals overvalued?
Does Poniard Pharmaceuticals pay dividends?
What is Poniard Pharmaceuticals’s EPS estimate?
How many shares outstanding does Poniard Pharmaceuticals have?
Which hedge fund is a major shareholder of Poniard Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert F. Caspari
- Employees
- 7
- Website
- www.poniard.com
- Address
- 300 Elliott Avenue West, Seattle, WA, 98119, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 3 |
| Technical Analysis | 1 | 0 | 3 |
| Moving Averages | 2 | 4 | 0 |

